CN101259131A - 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合给药 - Google Patents

用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合给药 Download PDF

Info

Publication number
CN101259131A
CN101259131A CNA2008100814220A CN200810081422A CN101259131A CN 101259131 A CN101259131 A CN 101259131A CN A2008100814220 A CNA2008100814220 A CN A2008100814220A CN 200810081422 A CN200810081422 A CN 200810081422A CN 101259131 A CN101259131 A CN 101259131A
Authority
CN
China
Prior art keywords
chemical compound
group
dimethyl
pyrroles
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2008100814220A
Other languages
English (en)
Chinese (zh)
Inventor
T·艾布拉姆斯
L·默里
N·普赖尔
J·M·彻林顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of CN101259131A publication Critical patent/CN101259131A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
CNA2008100814220A 2002-11-15 2003-11-14 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合给药 Pending CN101259131A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42638602P 2002-11-15 2002-11-15
US60/426,386 2002-11-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB200380103225XA Division CN100430060C (zh) 2002-11-15 2003-11-14 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合的制药用途

Publications (1)

Publication Number Publication Date
CN101259131A true CN101259131A (zh) 2008-09-10

Family

ID=32326343

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2008100814220A Pending CN101259131A (zh) 2002-11-15 2003-11-14 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合给药
CNB200380103225XA Expired - Fee Related CN100430060C (zh) 2002-11-15 2003-11-14 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合的制药用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB200380103225XA Expired - Fee Related CN100430060C (zh) 2002-11-15 2003-11-14 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合的制药用途

Country Status (22)

Country Link
US (1) US20040152759A1 (enExample)
EP (1) EP1562600A4 (enExample)
JP (1) JP2006508981A (enExample)
KR (1) KR20050086594A (enExample)
CN (2) CN101259131A (enExample)
AR (1) AR042042A1 (enExample)
AU (1) AU2003290943A1 (enExample)
BR (1) BR0315630A (enExample)
CA (1) CA2506308A1 (enExample)
CO (1) CO5700778A2 (enExample)
GT (1) GT200300245A (enExample)
MX (1) MXPA05005150A (enExample)
NL (1) NL1024779C2 (enExample)
NO (1) NO20052578L (enExample)
PA (1) PA8588601A1 (enExample)
PE (1) PE20040835A1 (enExample)
PL (1) PL376954A1 (enExample)
RU (1) RU2342140C2 (enExample)
TW (1) TW200418837A (enExample)
UY (1) UY28081A1 (enExample)
WO (1) WO2004045523A2 (enExample)
ZA (1) ZA200503841B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311811A (zh) * 2016-06-09 2019-02-05 有机合成药品工业株式会社 4-（哌啶-4-基）吗啉的制备方法

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100600550B1 (ko) * 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
EP1604665B1 (en) * 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
US7446124B2 (en) * 2004-07-09 2008-11-04 Prolx Pharmaceuticals Corp. Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
US8969379B2 (en) * 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US20090117197A1 (en) * 2005-03-21 2009-05-07 Vicus Therapeutics Llc Compositions and methods for ameliorating cachexia
CA2602316A1 (en) * 2005-03-23 2006-09-28 Pfizer Products Inc. Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
AU2006245421A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
DK1893213T3 (da) * 2005-06-03 2010-06-07 Novartis Ag Kombination af pyrimidylaminobenzamidforbindelser og imatinib til behandling eller forebyggelse af proliferative sygdomme
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
CN102716490A (zh) * 2005-09-01 2012-10-10 卫材R&D管理有限公司 药物组合物的崩解性的改善方法
CN101291950B (zh) * 2005-09-15 2013-01-02 科学与工业研究会 咪唑基取代的类固醇和茚满-1-酮衍生物
CN101267824A (zh) * 2005-09-20 2008-09-17 辉瑞产品公司 使用酪氨酸激酶抑制剂的治疗剂型和方法
KR101353763B1 (ko) 2005-11-07 2014-01-21 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 ｃ―ｋｉｔ 키나아제 저해 물질의병용
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
CN104706637A (zh) * 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
DE102006024834B4 (de) * 2006-05-24 2010-07-01 Schebo Biotech Ag Neue Indol-Pyrrol-Derivate und deren Verwendungen
US20090203693A1 (en) * 2006-06-29 2009-08-13 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US7855204B2 (en) * 2008-01-22 2010-12-21 Concert Pharmaceuticals Inc. Derivatives of gefitinib
WO2009096377A1 (ja) * 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. 血管阻害物質とタキサンとの併用
EP2318364A2 (en) * 2008-07-02 2011-05-11 Generics [UK] Limited Preparation of 3-pyrrole substituted 2-indolinone derivatives
US20100143295A1 (en) * 2008-12-05 2010-06-10 Auspex Pharmaceuticals, Inc. Quinazoline inhibitors of egfr tyrosine kinase
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CN103127096B (zh) * 2011-12-02 2015-11-25 杨子娇 吡咯基取代的吲哚类化合物在治疗青光眼病的应用
WO2013152193A2 (en) * 2012-04-04 2013-10-10 Beth Israel Deaconess Medical Center, Inc. Methods of treating proliferative disorders with malate or derivatives thereof
JPWO2014098176A1 (ja) 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN114585389A (zh) * 2019-09-26 2022-06-03 星法马私人有限公司 治疗性树枝状大分子

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0654024A1 (en) * 1992-08-06 1995-05-24 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
KR100743287B1 (ko) * 1998-05-29 2007-07-26 수젠, 인크. 피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제
JP5336686B2 (ja) * 1999-11-24 2013-11-06 スージェン， インク． 遊離酸または遊離塩基としてイオン化可能な医薬品のための処方
CA2395461C (en) * 1999-12-22 2010-05-25 Sugen, Inc. Methods of modulating c-kit tyrosine kinase function with indolinone compounds
HRP20020751B1 (hr) * 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
MY128449A (en) * 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
US6797725B2 (en) * 2001-04-09 2004-09-28 Sugen, Inc. Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311811A (zh) * 2016-06-09 2019-02-05 有机合成药品工业株式会社 4-（哌啶-4-基）吗啉的制备方法
CN109311811B (zh) * 2016-06-09 2022-09-09 有机合成药品工业株式会社 4-(哌啶-4-基)吗啉的制备方法

Also Published As

Publication number Publication date
PL376954A1 (pl) 2006-01-09
UY28081A1 (es) 2004-06-30
GT200300245A (es) 2004-06-23
NL1024779A1 (nl) 2004-05-18
KR20050086594A (ko) 2005-08-30
NO20052578L (no) 2005-05-27
ZA200503841B (en) 2006-09-27
WO2004045523A3 (en) 2004-09-30
RU2005118417A (ru) 2006-01-20
US20040152759A1 (en) 2004-08-05
JP2006508981A (ja) 2006-03-16
CN100430060C (zh) 2008-11-05
MXPA05005150A (es) 2005-07-22
TW200418837A (en) 2004-10-01
EP1562600A4 (en) 2008-06-25
EP1562600A2 (en) 2005-08-17
CO5700778A2 (es) 2006-11-30
AR042042A1 (es) 2005-06-08
CN1711089A (zh) 2005-12-21
PE20040835A1 (es) 2004-11-18
BR0315630A (pt) 2005-08-23
CA2506308A1 (en) 2004-06-03
AU2003290943A1 (en) 2004-06-15
PA8588601A1 (es) 2004-05-21
NL1024779C2 (nl) 2004-11-09
WO2004045523A2 (en) 2004-06-03
RU2342140C2 (ru) 2008-12-27

Similar Documents

Publication Publication Date Title
CN100430060C (zh) 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合的制药用途
JP7596441B2 (ja) （ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤
JP6963146B1 (ja) 癌を治療するためのｋｒａｓ阻害剤の投与
TWI680760B (zh) 治療黑色素瘤的藥物組合
KR20210005222A (ko) Rip1 억제 화합물 및 이를 제조하고 사용하는 방법
JP2020526572A (ja) パルボシクリブ及び６−（２，４−ジクロロフェニル）−５−［４−［（３ｓ）−１−（３−フルオロプロピル）ピロリジン−３−イル］オキシフェニル］−８，９−ジヒドロ−７ｈ−ベンゾ［７］アヌレン−２−カルボン酸を含む組み合わせ並びに癌の処置のためのその使用
KR20150023752A (ko) 암 및 자가면역 질환 치료에 유용한 가역적인 공유 피롤로- 또는 피라졸로피리미딘
ES2744198T3 (es) Formulaciones farmacéuticas, procesos, formas sólidas y procedimientos de uso relacionados con 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3, 4 dihidropirazino[2,3-b]pirazin-2(1H)-ona
JP2016512831A (ja) 重水素化されたパルボシクリブ
US10821114B2 (en) Derivatives of cephalosporin for treating cancer
TW202320792A (zh) 包含ｆｇｆｒ抑制劑及ｋｒａｓ抑制劑之組合療法
WO2022061201A1 (en) Compositions and methods for treating cancer
CN121758446A (zh) 咪唑酮类化合物及其制备方法和应用
JP2014005265A (ja) ピラゾール置換アミノ−ヘテロアリール化合物の誘導体
KR102959095B1 (ko) 사이클릭 디옥시리보뉴클레오티드 화합물
WO2023159184A1 (en) Drug combinations and methods of treating ovarian cancer
CN116444523A (zh) 作为smarca2抑制剂的化合物及其应用
WO2014081816A1 (en) Fluoro-derivatives of pyrazole-substituted amino-heteroaryl compounds
WO2026082160A1 (zh) Wee1蛋白降解剂及其应用
HK1120406A (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
CN117586265A (zh) 含氮杂环类化合物、其制备方法及其在医药上的应用
CN118632696A (zh) 包含fgfr抑制剂和kras抑制剂的组合疗法
CN121159504A (zh) Fgfr蛋白降解靶向嵌合体及其用途
JP2007507552A (ja) Ｉｇｆ１ｒ阻害剤が誘発する高血糖を治療する方法
HK40063264B (en) Cyclic deoxyribonucleotide compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1120406

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080910

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1120406

Country of ref document: HK